HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target

Cancers (Basel). 2019 Aug 7;11(8):1132. doi: 10.3390/cancers11081132.

Abstract

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, and gives rise to metastases in 50% of cases. The presence of an inflammatory phenotype is a well-known risk factor for the development of metastases. This inflammatory phenotype is characterized by the presence of high numbers of lymphocytes and macrophages, and a high expression of the HLA Class I and II antigens. An abnormal expression of HLA Class I may influence cytotoxic T lymphocyte (CTL) as well as Natural Killer (NK) cell responses. We provide a comprehensive review regarding the inflammatory phenotype in UM and the expression of locus- and allele-specific HLA Class I and of Class II antigens in primary UM and its metastases. Furthermore, we describe the known regulators and the role of genetics (especially chromosome 3 and BRCA-Associated Protein 1 (BAP1 status)), and, last but not least, the effect of putative therapeutic treatments on HLA expression.

Keywords: BAP1; HLA Class I; HLA Class II; chromosome 3; inflammation; uveal melanoma.

Publication types

  • Review

Grants and funding